


### Basic figure

<b>Issuer</b>	Opus - Chartered Iss. S.A.	<b>Index Sponsor</b>	i Partners SA
<b>ISIN</b>	DE000A3G2177	<b>Currency</b>	EUR
<b>NAV Date</b>	09.12.2025	<b>NAV</b>	1'345.42
<b>AUM</b>	22'260'000	<b>Components</b>	48
<b>Management Fee</b>	1.35%	<b>TER</b>	1.57%

### Investment strategy

Multi-asset certificate that aims to vary the asset allocation of our portfolios. It invests in equity, fixed income, precious metals and commodities without concentration limits. The objective is to seek the best possible positioning in each market situation. The investable universe consists of about 200 securities including ETFs and Big caps scattered around the world focusing more on the european markets. The benchmark index is composed of 50% equity, 25% short-term government bonds, and 25% commodities.


### Price chart



### Performance

	2025	2024	2023	2022
Jan	2.94	1.72	1.52	-6.81
Feb	2.29	5.61	-0.50	2.35
Mar	-4.32	5.99	-0.70	3.76
Apr	-5.32	-1.74	0.87	-2.89
May	1.66	0.39	2.65	2.37
Jun	-0.70	-1.29	2.81	-2.64
Jul	3.27	-0.26	-0.62	-1.49
Aug	2.13	0.83	-0.79	1.81
Sep	4.01	2.46	5.16	0.86
Oct	8.26	-0.22	1.19	3.03
Nov	-3.46	-0.06	-5.41	-2.52
Dec	1.12	1.65	1.89	-1.71
<b>YTD</b>	<b>11.62</b>	<b>15.82</b>	<b>7.97</b>	<b>-4.35</b>

### Asset Allocation



### Top 10 Holdings

SPDR Gold Shares	12.91%
WisdomTree Physical Silver	5.14%
Alphabet Inc	4.98%
Broadcom Inc	3.51%
ING Groep NV	3.49%
Roche Holding AG	3.36%
State Street SPDR S&P Biotech	3.36%
Astellas Pharma Inc	3.33%
Holcim AG	3.32%
Johnson & Johnson	3.31%

### Disclaimer

This document is for marketing purposes and it represents advertisement material and it is based on the prospectus. The content of this document has to be intended as a marketing communication issued by i Partners SA, Via Pretorio 9, 6900 Lugano (info@i-partners.ch). The present set of information are available only to professional investors resident in Switzerland within the meaning of art. 8(6), 68 FinSA, art. 95(1) FinSO. Its content is based upon information from deemed reliable sources, but it cannot be guaranteed as accurate, complete, valid or timely and it should not be relied on as such for any particular purpose. Any investment should be based solely on the prospectus, as well as the latest information available on the issuer webpage or on request. An investment in this product entails risks, which are fully described in the prospectus. Past performance is not a guide to future performance and may not be repeated. The value of an investment can rise or fall with market fluctuations and the originally invested amount be lost. Exchange rate changes may cause the value of any foreign investment to rise or fall.